Palatin Technologies, Inc. (PTN) FY2026 Earnings: Revenue $13M
PTN — FY2026 Annual Financial Report Analysis
Full Year · Fiscal year 2026 · Published by Pham Hop
Palatin's FY2026 net loss halved to $8.4M on $13.2M of one-time licensing income from Boehringer Ingelheim and Altanispac, but with $7.5M of cash the company flags going-concern doubt ahead of 2027 obesity-drug trials.
Revenue
$13M
Net income
-$8.4M
Diluted EPS
$-2.96
Operating margin
-65.7%
Palatin Technologies ended its fiscal year to June 30, 2026 with a much smaller loss than the year before — $8.4 million versus $17.3 million — but almost none of that improvement came from the drug-development business getting cheaper to run. It came from $13.2 million of one-time licensing income: Boehringer Ingelheim paid for a set of eye-disease compounds, and a small company called Altanispac took over the dry-eye drug PL9643. Palatin no longer sells any product (it sold its only approved drug, Vyleesi, to Cosette in December 2023), so this is a development-stage biotech whose results swing on deal payments, and its auditors again flagged substantial doubt about its ability to keep operating for the next twelve months with $7.5 million in the bank.
At a glance
$13.2M revenue vs. $0 a year earlier — all of it from licensing deals, not product sales; $3.75M of it arrived as a cancelled bill rather than cash.
$7.5M cash at June 30, 2026 — up from $2.6M, but only because Palatin raised $18.5M from selling shares and warrants; the company itself says this won't cover the next 12 months.
Loss per share fell from $32.15 to $2.96 — mostly because there are now about 5x as many shares (average 2.83M vs. 0.54M, after a 1-for-50 reverse split), not because the loss shrank that much.
The numbers
Metric
FY2026 (year to June 30, 2026)
FY2025
YoY Change
Collaboration & license revenue
$13.2M
$0
n/m
Research & development expense
$12.4M
$14.9M
Read 0 community reports on Palatin Technologies, Inc., or write your own.Write a report
-17.0%
General & administrative expense
$9.5M
$7.8M
+21.4%
Loss from operations
-$8.7M
-$17.5M
loss narrowed $8.8M
Operating margin
-65.7%
n/m (no revenue)
n/m
Net loss
-$8.4M
-$17.3M
loss narrowed $8.9M
Diluted EPS (loss per share)
-$2.96
-$32.15
loss per share narrowed $29.19
Cash used in operations
$13.5M
$21.3M
-36.5%
Cash & equivalents (year end)
$7.5M
$2.6M
+$4.9M
n/m = not meaningful (growth from zero, or percentage change between two losses). Operating margin — the share of revenue left after running the business — is deeply negative because costs still exceed the one-off deal income.
Where the revenue came from
All $13,185,031 of revenue came from two deals, per the 10-K:
Boehringer Ingelheim — $9.43M. In August 2025 the German drugmaker bought certain Palatin patent applications for melanocortin compounds aimed at retinal diseases (diabetic retinopathy and diabetic macular edema). Palatin received a €2.0M ($2.3M) upfront payment and a €5.5M ($6.5M) research milestone in September 2025; together those €7.5M (about $8.83M) were booked as revenue, with the remainder coming from reimbursed research work Palatin does for BI. The deal carries up to €280M (about $328M) in further development, regulatory and sales milestones plus royalties — but those are contingent, and BI, not Palatin, decides how fast the program moves.
Altanispac Labs — $3.75M. In January 2026 Palatin sublicensed PL9643, its dry-eye drug that completed one Phase 3 trial (MELODY-1, 575 patients; it hit the co-primary pain endpoint), to Altanispac. The "upfront payment" was not cash: the filing states the $3,751,122 "was received in the form of non-cash debt cancellation" and that "the canceled debt was previously recorded in current liabilities." Altanispac now runs the remaining MELODY-2 and MELODY-3 trials; Palatin is due future sublicensing/sale payments and royalties if the drug succeeds.
Where the money went
R&D fell $2.5M to $12.4M. The drop was all in program spending: money spent on the MC4R obesity programs and other preclinical work fell from $8.55M to $6.07M (-29%), which the filing attributes to "a decrease in spending on our MC4R programs." General R&D overhead was flat ($6.30M vs. $6.35M). In other words, the core obesity pipeline got less funding this year while the company waited for cash.
G&A rose $1.7M to $9.5M, which management attributes "primarily" to "an increase in consulting fees." For a company this size, overhead now almost equals R&D — $9.5M of administration against $12.4M of research.
What the headline numbers hide
The loss didn't shrink because costs fell. Total operating costs before one-off gains were about flat: $21.9M this year vs. $22.7M last year (FY2025's reported $17.5M figure was reduced by two one-time gains — $3.13M from settling Vyleesi sale milestones and $2.12M from renegotiating a manufacturing purchase commitment). Strip out those FY2025 gains and the year-ago net loss was about $22.6M; strip the non-cash Altanispac revenue from this year and the FY2026 loss is about $12.1M. The improvement is real, but it is deal income, not a leaner business — and deal income doesn't repeat on a schedule.
About $3.75M of revenue brought in no cash. It cleared a bill instead. That still helped: accounts payable fell from $7.0M to $1.1M — $3.75M wiped out by the Altanispac deal and about $2.1M paid down in cash. The balance sheet is much cleaner (stockholders' equity swung from a $4.8M deficit to +$6.7M), but the cash statement shows the real picture: operations still consumed $13.5M despite roughly $8.8M of BI payments coming in.
Loss per share is flattered by dilution. The weighted-average share count rose from 538,348 to 2,827,233 after the November 2025 offering (about $18.2M gross, at $6.50 per share plus warrants). That — not operations — is why EPS went from -$32.15 to -$2.96. And the overhang is large: as of September 25, 2026 there were 8,763,962 shares underlying outstanding preferred stock, options, restricted stock units and warrants, against 1,779,275 common shares outstanding at June 30.
The listing was fragile. NYSE American suspended trading in May 2025; the stock traded over the counter until November 2025 after a 1-for-50 reverse split, and in May 2026 the company moved to the Nasdaq Capital Market, which requires at least $2.5M of stockholders' equity (Palatin had $6.7M at year end) and a $1.00 minimum bid price.
Takeaway: FY2026's smaller loss was bought with one-time asset sales — the BI patent deal and the PL9643 sublicense — while the company's own obesity programs got 29% less money. With $7.5M of cash, a stated going-concern doubt, and last year's $13.5M operating cash burn already cushioned by ~$8.8M of BI payments that won't recur unless a milestone hits, Palatin will almost certainly need to raise more money (likely diluting shareholders again) before its first obesity drug reaches a Phase 1 trial in 2027.
What to watch next
Cash runway. Management states plainly that the $7.5M it holds is not enough to fund operations for twelve months from the filing date, even counting its ability to "reduce or delay certain expenditures." As rough arithmetic (ours, not the company's): at FY2026's $13.5M operating cash use — about $1.1M a month — $7.5M lasts around six to seven months, and that pace was helped by BI money. Expect an equity raise, a new partnership, or pipeline cuts in the coming months. One structural detail: the Series J warrants ($6.50 exercise price) expire 31 days after the FDA accepts an Investigational New Drug (IND) application for an in-house obesity compound, which gives holders a reason to exercise — and Palatin a potential cash inflow — right around that milestone.
Pipeline catalysts, per the 10-K:
Once-weekly MC4R peptide (injectable, aimed at rare obesity disorders such as hypothalamic obesity and Prader-Willi syndrome): Phase 1 trial planned for the first half of calendar 2027. MC4R is a brain receptor that controls appetite; drugs that activate it can reduce hunger in patients whose appetite-signalling pathway is broken.
Oral small-molecule MC4R agonist (a pill, building on the earlier PL7737 work): IND-enabling studies in the first half of 2027, Phase 1 in the second half of 2027.
Partnered assets: future BI milestones (up to €280M total) and PL9643's MELODY-2/-3 trials at Altanispac. Both could pay Palatin, but neither is on a timetable Palatin controls.
Programs for sale: bremelanotide (Vyleesi's active ingredient) combined with tirzepatide for obesity — its Phase 2 showed 4.4% weight loss vs. 1.6% for placebo over eight weeks — plus oral PL8177 for ulcerative colitis and a diabetic kidney-disease program. Palatin says it will not fund any of these itself and is seeking partners; a licensing deal would be the most direct non-dilutive cash source.
Our read: FY2026 showed Palatin can turn shelved assets into cash, which kept it alive. But what remains in-house is two preclinical obesity programs whose first human trials are a year or more away, a funding gap the company itself acknowledges, and an options/warrants overhang nearly five times the common share count. The next 10-Q will show whether FY2027 opens with another deal or another raise; either way, the obesity timelines are stated as "subject to the availability of appropriate funding."